Longvida®
Research
Longvida®
Research
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Investigation of the lymphatic transport of solid-lipid curcumin particles (Longvida®) in comparison to curcumin extract in rats.
Eidenberger T et al.
University of Applied Sciences, Upper Austria. Poster in 252nd ACS National Meeting: Philadelphia, PA. 2016 Aug. P55.
Longvida enters the lymphatic system via chylomicrons; from lymphatic circulation, free curcumin is released into systemic circulation. Five times higher relative bioavailability of free curcumin in plasma and 10-fold higher concentrations of free curcumin in the lymph were detected after administration of Longvida when compared to the standard curcumin; further confirming lymphatic transport.
A comparative study of dietary curcumin, Longvida®, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of mice.
Maiti P et al.
Histochem Cell Biol. 2016 Jul. doi: 10.1007/s00418-016-1464-1
At nanomolar concentrations, Longvida was found sufficient for labeling and imaging of Aβ plaques in 5×FAD brain tissue when compared to dietary curcumin and other amyloid-binding dyes.
Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin.
McFarlin et al.
University of North Texas. BBA Clinical. 2016 Feb 18. 5: 72-78. doi: 10.1016/j.bbacli.2016.02.003
Collectively, the findings demonstrated that consumption of Longvida (400mg/day) reduced key inflammatory biomarkers during recovery after exercise-induced muscle damage (EIMD). The observed improvements in biological inflammation may translate to faster recovery and improved functional capacity during subsequent exercise sessions.
Examining the potential clinical value of curcumin.
Goozee KG et al.
British J Nutr. 2016. 115: 449-465. doi: 10.1017/S0007114515004687
Curcumin supplement improves vascular endothelial function in middle-aged and older adults.
Santos-Parker JR et al.
Geront. 2015 Dec. 55(Suppl 2): 195. doi: 10.1093/geront/gnv554.01
Longvida administered at a dose of 2000mg/day (n=16), or placebo (n=13) for 12 weeks increased brachial artery flow-mediation dilation (FMDba) by 34% and forearm blood flow in response to incremental brachial artery infusions of acetylcholine (FBFach) by 44% in middle-aged and older (MA/O) adults (45-74 yrs). Findings support supplementation with Longvida improves endothelial-dependent dilation (EDD) in MA/O adults mediated, in part, by an increase in nitric oxide bioavailability.
Anti-inflammatory effects of novel standardized solid lipid curcumin formulations.
Nahar PP et al.
University of Rhode Island, J Med Food. July 2015. 18(7): 786-792. doi: 10.1089/jmf.2014.0053
As part of the Verdure Botanical Active Testing System (VBATS), Longvida and Longvida SD (Solution Dispersible) both reduced inflammatory markers NF-kB, TNF-a, and cytokines in immune-compromised cells (macrophages). The improved effects are thought to be due to an exponential increase in the water solubility of Longvida forms versus regular curcumin.
Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population.
Cox KH et al.
Centre for Human Psychopharmacology, Swinburne University. J Psychopharmacol. 2015 May. Vol 29(No 5): 642-651. doi: 10.1177/0269881114552744
This landmark study is one of the first to show a curcumin supplement improves cognitive function in healthy subjects. The trial recruited 60 subjects aged 60-80, and found daily Longvida (400mg) supplementation led to significant improvements in cognitive function versus the placebo group. Excellent safety was reported, including no dropouts or reports of gastrointestinal upset. Significant improvements were observed in measures for memory, attention, fatigue, stress, and mood in as little as one hour after the first dose.
Efficacy of curcumin in the treatment for oral health – A randomized clinical trial.
Hazarey VK et al.
Government Dental College and Hospital. Nagpur, Maharashtra, India. J Oral Maxillofac Pathol. 2015. 19: 145-52. doi: 10.4103/0973-029X.164524
A randomized, controlled clinical trial in 30 clinically diagnosed patients with OSF concluded that Longvida lozenges could be effective in combination strategies for the management of OSF in comparison to single therapeutic modality. In this study, 15 OSF patients in each group (test & control) were treated with either Longvida lozenges (400 mg lozenges for total daily dose of 2 g) or Tenovate ointment (clobetasol propionate (0.05%)). The treatment was given for 3 months and follow-up was done for 6 months.
The biomarker initiative DSBI pilot: Proof of concept for deep phenotyping of biomarkers.
Rafii MS et al.
Front Behav Neurosci. 2015. 9: 1-11.
Retina, being part of the CNS, has previously been difficult to analyze directly; however, retinal amyloid imaging could now be a tool to demonstrate the presence of plaques in the brain in a non-invasive manner. In line with previous findings, this study supports Longvida quickly labeling retinal beta amyloid and inducing fluorescent plaque in the neural layers of the retina of humans.
Clinical development of curcumin in neurodegenerative disease.
Hu S et al.
Expert Rev Neurother. 2015. 15(6): 629-637. doi: 10.1586/14737175.2015.1044981
Development of a neuroprotective potential algorithm for medicinal plants.
Liu W et al.
University of Rhode Island. Neurochem Int. 2016 Sep 29. 100: 164-177.
As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation. Bacognize showed the highest in anti-Aβ fibrillation in both methods.
Retinal amyloid fluorescence imaging predicts cerebral amyloid burden.
Frost S et al.
Alz Dement. 2014. 10(4): P234-P235.
Retinal Aβ plaques are similar to plaques in the brain. Longvida’s ability to cross the BBB and its affinity for binding to amyloid beta have led to its use as a novel, more cost-effective alternative and imaging tool for screening through the eyes.
Longvida effectively modulates the development of reovirus 1/L-induced ARDS in both a prophylactic and therapeutic model.
Stony Brook University. 2014. Unpublished.
After treatment with Longvida, beginning on day seven post-inoculation, reovirus 1/L-ARDS mice exhibited a significant reduction in the development of fibrotic lesions.
Absorption of curcumin into lymph and plasma using an enhanced solid-lipid dose delivery form in rats.
2014. Unpublished.
It is well known that curcumin undergoes extensive first-pass metabolism yielding high amounts of curcumin-glucuronide in the blood after oral administration. The plasma and the lymphatic concentrations of curcumin are about 5-fold and 10-fold higher after administration of Longvida when compared to the standard curcumin suspension, respectively. The high amount of curcumin found in the lymphatic fluid after treatment with Longvida serves as explanation for its increased bioavailability when compared to the standard curcumin suspension.
Curcumin [Longvida®] suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice.
Ma et al.
J Biol Chem. 2013 Feb 8. 288(6): 4056-65. doi: 10.1074/jbc.M112.393751
This National Institutes of Health (NIH) and Veterans Administration (VA) funded research at UCLA published in a premier journal, is believed to be one of the first to show a nutritional intervention can remove a highly toxic type of soluble tau in live models, which directly led to memory improvement. Also believed to be the first paper to show a substance can reduce the creation of new tau by modulation of the creation of ‘sticky’ or phosphorylated tau by heat shock protein in vivo. In this study, therapeutic brain levels of free curcumin were also detected after chronic low-dose Longvida dosing.
Don’t see what you’re looking for? All additional research is categorized under supportive research.
Investigation of the lymphatic transport of solid-lipid curcumin particles (Longvida®) in comparison to curcumin extract in rats.
Eidenberger T et al.
University of Applied Sciences, Upper Austria. Poster in 252nd ACS National Meeting: Philadelphia, PA. 2016 Aug. P55.
Longvida enters the lymphatic system via chylomicrons; from lymphatic circulation, free curcumin is released into systemic circulation. Five times higher relative bioavailability of free curcumin in plasma and 10-fold higher concentrations of free curcumin in the lymph were detected after administration of Longvida when compared to the standard curcumin; further confirming lymphatic transport.
A comparative study of dietary curcumin, Longvida®, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of mice.
Maiti P et al.
Histochem Cell Biol. 2016 Jul. doi: 10.1007/s00418-016-1464-1
At nanomolar concentrations, Longvida was found sufficient for labeling and imaging of Aβ plaques in 5×FAD brain tissue when compared to dietary curcumin and other amyloid-binding dyes.
Reduced inflammatory and muscle damage biomarkers following oral supplementation with bioavailable curcumin.
McFarlin et al.
University of North Texas. BBA Clinical. 2016 Feb 18. 5: 72-78. doi: 10.1016/j.bbacli.2016.02.003
Collectively, the findings demonstrated that consumption of Longvida (400mg/day) reduced key inflammatory biomarkers during recovery after exercise-induced muscle damage (EIMD). The observed improvements in biological inflammation may translate to faster recovery and improved functional capacity during subsequent exercise sessions.
Examining the potential clinical value of curcumin.
Goozee KG et al.
British J Nutr. 2016. 115: 449-465. doi: 10.1017/S0007114515004687
Curcumin supplement improves vascular endothelial function in middle-aged and older adults.
Santos-Parker JR et al.
Geront. 2015 Dec. 55(Suppl 2): 195. doi: 10.1093/geront/gnv554.01
Longvida administered at a dose of 2000mg/day (n=16), or placebo (n=13) for 12 weeks increased brachial artery flow-mediation dilation (FMDba) by 34% and forearm blood flow in response to incremental brachial artery infusions of acetylcholine (FBFach) by 44% in middle-aged and older (MA/O) adults (45-74 yrs). Findings support supplementation with Longvida improves endothelial-dependent dilation (EDD) in MA/O adults mediated, in part, by an increase in nitric oxide bioavailability.
Anti-inflammatory effects of novel standardized solid lipid curcumin formulations.
Nahar PP et al.
University of Rhode Island, J Med Food. July 2015. 18(7): 786-792. doi: 10.1089/jmf.2014.0053
As part of the Verdure Botanical Active Testing System (VBATS), Longvida and Longvida SD (Solution Dispersible) both reduced inflammatory markers NF-kB, TNF-a, and cytokines in immune-compromised cells (macrophages). The improved effects are thought to be due to an exponential increase in the water solubility of Longvida forms versus regular curcumin.
Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population.
Cox KH et al.
Centre for Human Psychopharmacology, Swinburne University. J Psychopharmacol. 2015 May. Vol 29(No 5): 642-651. doi: 10.1177/0269881114552744
This landmark study is one of the first to show a curcumin supplement improves cognitive function in healthy subjects. The trial recruited 60 subjects aged 60-80, and found daily Longvida (400mg) supplementation led to significant improvements in cognitive function versus the placebo group. Excellent safety was reported, including no dropouts or reports of gastrointestinal upset. Significant improvements were observed in measures for memory, attention, fatigue, stress, and mood in as little as one hour after the first dose.
Efficacy of curcumin in the treatment for oral health – A randomized clinical trial.
Hazarey VK et al.
Government Dental College and Hospital. Nagpur, Maharashtra, India. J Oral Maxillofac Pathol. 2015. 19: 145-52. doi: 10.4103/0973-029X.164524
A randomized, controlled clinical trial in 30 clinically diagnosed patients with OSF concluded that Longvida lozenges could be effective in combination strategies for the management of OSF in comparison to single therapeutic modality. In this study, 15 OSF patients in each group (test & control) were treated with either Longvida lozenges (400 mg lozenges for total daily dose of 2 g) or Tenovate ointment (clobetasol propionate (0.05%)). The treatment was given for 3 months and follow-up was done for 6 months.
The biomarker initiative DSBI pilot: Proof of concept for deep phenotyping of biomarkers.
Rafii MS et al.
Front Behav Neurosci. 2015. 9: 1-11.
Retina, being part of the CNS, has previously been difficult to analyze directly; however, retinal amyloid imaging could now be a tool to demonstrate the presence of plaques in the brain in a non-invasive manner. In line with previous findings, this study supports Longvida quickly labeling retinal beta amyloid and inducing fluorescent plaque in the neural layers of the retina of humans.
Clinical development of curcumin in neurodegenerative disease.
Hu S et al.
Expert Rev Neurother. 2015. 15(6): 629-637. doi: 10.1586/14737175.2015.1044981
Development of a neuroprotective potential algorithm for medicinal plants.
Liu W et al.
University of Rhode Island. Neurochem Int. 2016 Sep 29. 100: 164-177.
As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation. Bacognize showed the highest in anti-Aβ fibrillation in both methods.
Retinal amyloid fluorescence imaging predicts cerebral amyloid burden.
Frost S et al.
Alz Dement. 2014. 10(4): P234-P235.
Retinal Aβ plaques are similar to plaques in the brain. Longvida’s ability to cross the BBB and its affinity for binding to amyloid beta have led to its use as a novel, more cost-effective alternative and imaging tool for screening through the eyes.
Longvida effectively modulates the development of reovirus 1/L-induced ARDS in both a prophylactic and therapeutic model.
Stony Brook University. 2014. Unpublished.
After treatment with Longvida, beginning on day seven post-inoculation, reovirus 1/L-ARDS mice exhibited a significant reduction in the development of fibrotic lesions.
Absorption of curcumin into lymph and plasma using an enhanced solid-lipid dose delivery form in rats.
2014. Unpublished.
It is well known that curcumin undergoes extensive first-pass metabolism yielding high amounts of curcumin-glucuronide in the blood after oral administration. The plasma and the lymphatic concentrations of curcumin are about 5-fold and 10-fold higher after administration of Longvida when compared to the standard curcumin suspension, respectively. The high amount of curcumin found in the lymphatic fluid after treatment with Longvida serves as explanation for its increased bioavailability when compared to the standard curcumin suspension.
Curcumin [Longvida®] suppresses soluble tau oligomers and corrects molecular chaperone, synaptic and behavioral deficits in aged human tau transgenic mice.
Ma et al.
J Biol Chem. 2013 Feb 8. 288(6): 4056-65. doi: 10.1074/jbc.M112.393751
This National Institutes of Health (NIH) and Veterans Administration (VA) funded research at UCLA published in a premier journal, is believed to be one of the first to show a nutritional intervention can remove a highly toxic type of soluble tau in live models, which directly led to memory improvement. Also believed to be the first paper to show a substance can reduce the creation of new tau by modulation of the creation of ‘sticky’ or phosphorylated tau by heat shock protein in vivo. In this study, therapeutic brain levels of free curcumin were also detected after chronic low-dose Longvida dosing.
